FDA orphan drug designation: treatment of transthyretin-mediated amyloidosis
All entries for: Purpose Pharma International AB
July 3, 2025
Purpose Pharma International AB
Orphan Drug Designation
Disease Area: Rare Diseases
FDA orphan drug designation: treatment of transthyretin-mediated amyloidosis
